New report provides a policy framework to support countries in implementing an effective life-course approach to immunization

“Implementing a Life-Course Approach to Immunization” launched along the sidelines of the European Commission and World Health Organization Global Vaccination Summit

GENEVA, 12 September 2019 – The report “Implementing a Life-Course Approach to Immunization” provides a policy framework for countries to implement effective policies in order to maximize individual and population-wide health and economic benefits of a life-course approach to immunization. A life-course approach requires that immunization schedules and access to vaccination respond to an individual’s stage in life, their lifestyle and specific vulnerabilities/risks to infectious disease that they may face during the life-course.

Designed for policy makers and healthcare professionals, the report draws on research from six countries, Australia, Japan, France, Brazil, the United Kingdom and the United States of America, and their experience in controlling vaccine-preventable diseases by implementing a life-course approach to immunization.

Successful and innovative approaches are being implemented with lessons that may inform immunization policies and programs in other contexts. In addition, a life-course approach to immunization can improve health, support health system sustainability, and promote economic prosperity.

Despite the recognized benefits, countries are at different stages of implementing a life-course approach to immunization with a few doing so comprehensively. As a result, many of the goals set by the World Health Organization in the Global Vaccine Action Plan will not be achieved by 2020, and there is an urgent need to implement policies that promote vaccination coverage across the life course.

As ageing populations put increasing pressure on health systems, vaccine hesitancy is on the rise and the toll of AMR continues unabated, implementing effective life-course immunization strategies remains a critical policy priority and opportunity.

The report was compiled by Health Policy Partnership (HPP) on the basis of desk research and expert interviews with funding from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).


About the IFPMA:
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

For further information, please contact: communications@ifpma.org